Last reviewed · How we verify

Richard H. Haas — Portfolio Competitive Intelligence Brief

Richard H. Haas pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Low dose levetiracetam Low dose levetiracetam marketed Antiepileptic agent SV2A (synaptic vesicle protein 2A) Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Children's Hospital of Fudan University · 1 shared drug class
  2. Generic (originally UCB Pharma) · 1 shared drug class
  3. GlaxoSmithKline · 1 shared drug class
  4. Hospices Civils de Lyon · 1 shared drug class
  5. Mario Negri Institute for Pharmacological Research · 1 shared drug class
  6. ayesha tariq · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Richard H. Haas:

Cite this brief

Drug Landscape (2026). Richard H. Haas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/richard-h-haas. Accessed 2026-05-16.

Related